@yuliyakadr's GLP-1 claims need some fact-checking
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways. Clinical trials show 15-21% weight loss when combined with lifestyle modifications, but gastrointestinal side effects affect the majority of users.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
Without being able to see the specific content of @yuliyakadr's TikTok, we can't analyze her exact claims about GLP-1 medications. This is already a problem.
TikTok videos about semaglutide, tirzepatide, and similar medications typically cover topics like rapid weight loss, side effects, dosing schedules, or personal experience stories. The platform's algorithm tends to amplify dramatic success stories or extreme side effect warnings, neither of which gives you the full picture.
What we can tell you is that any video racking up 200K+ views about these medications deserves scrutiny. The stakes are too high for casual medical advice.
What does the actual science say about GLP-1s?
The clinical trial data for these medications is strong, but it's also specific. Let's stick to what we actually know.
The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss at 68 weeks with 2.4mg semaglutide weekly versus 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 20.9% weight loss with 15mg tirzepatide weekly at 72 weeks.
Both studies required lifestyle modifications alongside medication. The FDA approval for Wegovy specifically states it's for adults with BMI ≥30 or BMI ≥27 with weight-related conditions, combined with reduced-calorie diet and exercise.
Where do TikTok creators usually go wrong?
Most TikTok content about GLP-1 medications falls into predictable traps. They oversimplify complex dosing schedules or ignore contraindications entirely.
Common mistakes include claiming these medications work without lifestyle changes (they don't work as well), suggesting everyone can access them easily (insurance coverage is complicated), or downplaying gastrointestinal side effects that affect 44% of users in clinical trials.
Another frequent error: mixing up the medications. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) work differently. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide only hits GLP-1.
What should you actually know about these medications?
Start with this: they're prescription medications that require medical supervision. Period.
The starting dose for semaglutide is 0.25mg weekly, escalated over 16-20 weeks to 2.4mg for weight management. Tirzepatide starts at 2.5mg weekly and can go up to 15mg. These aren't supplements you order online.
Cost matters too. Without insurance, Wegovy runs about $1,300 monthly. Zepbound is similar. Even with coverage, your copay could hit $25-100 monthly depending on your plan.
Side effects are real and common. In the STEP trials, 74% of semaglutide users experienced gastrointestinal issues versus 48% on placebo. That's not a minor detail to gloss over in a 30-second video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @yuliyakadr's GLP-1 claims need some fact-checking, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@yuliyakadr's GLP-1 claims need some fact-checking is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways. Clinical trials show 15-21% weight loss when combined with lifestyle modifications, but gastrointestinal side effects affect the majority of users.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways. Clinical trials show 15-21% weight loss when combined with lifestyle modifications, but gastrointestinal side effects affect the majority of users.
- Semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in the STEP 1 trial, but only when combined with lifestyle changes
- Tirzepatide showed higher efficacy at 20.9% weight loss in SURMOUNT-1, but targets different receptors than semaglutide
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in the STEP 1 trial, but only when combined with lifestyle changes
- Tirzepatide showed higher efficacy at 20.9% weight loss in SURMOUNT-1, but targets different receptors than semaglutide
- 74% of semaglutide users experienced gastrointestinal side effects in clinical trials versus 48% on placebo
- FDA approval requires BMI ≥30 or BMI ≥27 with weight-related conditions, not just desire to lose weight
- Monthly costs range from $1,300+ without insurance, with variable coverage and copays of $25-100
- Dosing starts at 0.25mg weekly for semaglutide and escalates slowly over 16-20 weeks to avoid side effects
- Both medications require ongoing medical supervision and aren't available as over-the-counter supplements
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Julia K. · TikTok creator
201.8K views on this video
@yuliyakadr's GLP-1 claims need some fact-checking
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Julia K., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.